CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue has announced today the release of exciting new data illustrating the performance of its proprietary InSituPlex™ technology that powers the company’s reagent offering. Ultivue’s high- quality, kit-based products enable unsurpassed protein biomarker detection and analysis in tissue, with no compromise on level of multiplexing or sample staining and imaging throughput, and with no requirement of dedicated instrumentation. Dr. Michael Natan, Ultivue’s Chief Executive Officer, “We are very excited to demonstrate, through a compelling data set, that our products provide the performance and flexibility demanded in a wide range of use cases from clinical research and translational research to discovery applications.”
Ultivue’s scientific team is presenting 4 posters at the Emerging Proteomic Technologies for Cancer Research poster session on Wednesday 18 April, 2018 from 8:00 AM to 12.00 PM. Attendees at this important meeting (April 14-18, Chicago, IL), will gain insight into how an array of cancer types, including Non-Small Cell Lung Cancer (NSCLC), melanoma and breast carcinomas, can easily be interrogated for the presence of immuno-oncology markers using Ultivue’s ImmunoProfiler kits on a single slide, and with single staining, signal amplification, and imaging steps. The posters also illustrate benchmarked equivalent performance vs. conventional DAB and TSA-based immuno-histochemistry methods. However, compared to TSA-based approaches, Ultivue’s InSituPlex technology provides the important added benefits of (i) higher multiplexing level on single slide for whole slide imaging, (ii) dramatically improved usability, (iii) enhanced workflow integration, and (iv) preservation of sample integrity for downstream experiments.
“In addition to delivering excellent data quality, our assay panels seamlessly integrate with common immunohistochemistry workflows to deliver fast, high quality sample-to-image data. Up to 30 individual tissue sample slides are routinely stained in our labs, as a single batch, using an optimized, automated protocol. Within a work day, all 30 samples are stained and imaged as whole slides with a conventional multispectral scanner”, says Philippe Mourere, SVP Commercial Operations. “Such throughput provides significant gains of productivity to those labs requiring fast and detailed sample-to-data tumor profiling information”, adds Mourere.
Ultivue’s scientific personnel will be present at the company booth #3402 throughout the duration of the meeting conference to engage with the scientific community.
Founded by two core faculty from the Wyss Institute at Harvard
University˗ David Walt, a world-leading expert in biomolecular analysis,
and Peng Yin, a pioneer in DNA nanotechnology˗ Ultivue is a
venture-backed company developing reagent-driven solutions for
high-performance biological imaging in situ, combining unlimited
multiplexing at high speed with high spatial resolution. Ultivue’s
proprietary solutions will enable researchers and clinicians to realize
the promise of personalized medicine through better matching of patients
to therapeutic options. The company is launching products and services
that seamlessly integrate into existing workflows for biomarker
discovery, assay validation, and companion diagnostic applications.
Ultivue is based in Cambridge, MA.
To learn more, visit www.ultivue.com